DexCom Inc. (NASDAQ:DXCM) finished Friday with a subtraction of -$1.53 to close at $566.57, a downside of -0.27 percent. An average of 472,480 shares of common stock have been traded in the last five days. There was a gain of $22.10 in the past week, and it reached a new high 27 times over the past 12 months. The last 20 days have seen an average of 490,605 shares traded, while the 50-day average volume stands at 495,302.
DXCM stock has decreased by -1.08% in the last month. The company shares reached their 1-month lowest point of $521.01 on 10/04/21. With the stock rallying to its 52-week high on 09/23/21, shares of the company touched a low of $305.63 and a high of $579.00 in 52 weeks. It has reached a new high 35 times so far this year and achieved 53.24% or $196.85 in price. In spite of this, the price is down -2.15% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
8 days have passed since DexCom Inc. (DXCM) last reported insider trading activity. SAYER KEVIN R, who is Chairman, CEO & President, most recently acquired $6,000 shares at $549.22 per share on Oct 15. In this transaction, the insider spent $3,295,334. EVP, Global Marketing, Patterson Chad, disposed of 141 shares at a price of $545.54 on Oct 13. The insider now owns more than $76,921 worth of shares. Prior to that, Director FOLETTA MARK G went on to Sale 500 shares at $543.09 each on Oct 01. An amount of $271,547 was transacted.
DexCom Inc. (DXCM) has a trailing price-to-earnings (P/E) ratio of 106.10, which compares with the 26.50 for the broader industry and 33.43 for the sector. In the last five years, DexCom Inc.’s PE ratio has ranged between 318.00 and 61.71. The stock’s beta is 0.69. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 25.73, the price-to-book (PB) ratio at 27.42, and the price-to-cash flow ratio at 555.46.
The quick ratio of DexCom Inc. for the three months ended June 29 was 5.30, and the current ratio was 5.80, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.89 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at $1.28 billion compared to revenue of $1.93 billion.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, DexCom Inc.’s return on assets was 12.50%. For the broader industry, ROE averaged -2.89 over the past year.
In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $62.9 million in the quarter, while revenues were grew 26.39%. The analyst consensus anticipated DexCom Inc.’s latest quarter earnings to come in at $0.44 per share, but it turned out to be $0.76, a 72.70% surprise. For the quarter, EBITDA amounted to $124.5 million. Shareholders own equity worth $96.75 million.
From a technical analysis perspective, let’s take a brief look at DexCom Inc. (DXCM) price momentum. RSI 9-day as of the close on 22 October was 64.57%, suggesting the stock is Neutral, with historical volatility in this time frame at 19.09%.
As of today, DXCM’s price is $556.51 +4.06% or $22.10 from its 5-day moving average. DXCM is currently trading +1.04% higher than its 20-day SMA and +52.72% higher than its 100-day SMA. However, the stock’s current price level is +14.96% above the SMA50 and +46.34% above the SMA200.
The stochastic %K and %D were 93.10% and 83.24%, respectively, and the average true range (ATR) was 14.20. With the 14-day stochastic at 92.99% and the average true range at 14.63, the RSI (14) stands at 60.84%. The stock has reached 11.73 on the 9-day MACD Oscillator while the 14-day reading was at 17.50.
Guggenheim downgraded DexCom Inc. (NASDAQ: DXCM) to a a Neutral rating in its most recent analyst report. Previously, the stock was rated as a Buy. The consensus rating for DexCom Inc. (DXCM) among analysts is Overweight. According to current brokerage recommendations, 1 brokerage firm advise that investors sell DXCM, while 5 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 3 analysts, while 15 others rate it as a “buy”.
What is DXCM’s price target for the next 12 months?
Analysts predict a range of price targets between $475.00 and $650.00, with a median target of $522.50. Taking a look at these predictions, the average price target given by analysts for DexCom Inc. (DXCM) stock is $544.10.